Please login to the form below

Not currently logged in

Novartis joins UAM

Novartis has become the first healthcare company to join United Against Malaria (UAM)

Novartis has become the first healthcare company to join United Against Malaria (UAM), a consortium that strives to raise awareness of malaria and achieve the shared goal of ending malaria deaths in Africa by 2015. 

The announcement was made by chairman and CEO of Novartis, Dr Daniel Vasella, on delivery of the 250 millionth treatment of Coartem, an artemisinin-based combination therapy (ACT) for the treatment of malaria to Mwananyamala District Hospital in Dar es Salaam, Tanzania. 

According to Dr Vasella: "The Novartis Malaria Initiative is the industry's largest access-to-medicines programme in the developing world, however, malaria demands a collaborative approach. Joining United Against Malaria in its campaign is a promising way to relieve unnecessary suffering due to malaria."

Preventable and curable, malaria remains a devastating disease infecting more than 250 million people each year and causing an estimated 880,000 deaths. Its toll is heaviest among young children in sub-Saharan Africa, where it is estimated that a child dies of malaria every 30 seconds.

6th July 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...